Moderna, Inc. and Immatics N.V. announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need. This broad multi-platform collaboration will leverage the deep scientific expertise and core operational capabilities of both companies, combining Immatics' TCR platform with Moderna's cutting-edge mRNA technology, and span various therapeutic modalities including bispecifics, cell therapy and cancer vaccines.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.96 USD | +1.39% | +1.20% | +4.08% |
May. 15 | Mizuho Raises Immatics' Price Target to $16 From $14, Keeps Buy Rating | MT |
May. 14 | Immatics' Q1 Loss Narrows. Revenue Rises | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
132.9 USD | +0.17% | +13.29% | 50.93B | ||
10.96 USD | +1.39% | +1.20% | 1.13B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.08% | 1.13B | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- IMTX Stock
- News Immatics N.V.
- Moderna, Inc. and Immatics N.V. Announces Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics